MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Centre Francois Baclesse
- Enrollment
- 104
- Locations
- 6
- Primary Endpoint
- Evaluate the sensitivity of MoCA test
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This study concerns elderly patients with cancer with onco-geriatric assessment.
This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient aged over 70 years
- •Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.
- •Patient candidate for oncogeriatric assessment
- •Patient agree to participate in the study
- •Using the French language
Exclusion Criteria
- •Primary central nervous system or cerebral metastasis
- •Evolutionary psychiatric pathology known (e.g. schizophrenia)
- •Severe Visual and / or Auditory Impairment
- •Patients unable to respond to cognitive tests
- •Patient (s) deprived of liberty, under guardianship or curatorship
- •Refusal of participation
Outcomes
Primary Outcomes
Evaluate the sensitivity of MoCA test
Time Frame: Up 2 months after inclusion, before initiation of treatment
MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%